Stocks of Zura Bio Ltd (NASDAQ:ZURA) traded higher last session on Wall Street, down -1.67% to $1.77.
ZURA stock price is now -37.56% away from the 50-day moving average and -52.27% away from the 200-day moving average. The market capitalization of the company currently stands at $115.57M.
With the price target of $15, Leerink Partners recently initiated with Outperform rating for Zura Bio Ltd (NASDAQ: ZURA). On September 05, 2024, H.C. Wainwright recently initiated its ‘Neutral’ rating on the stock quoting a target price of $5, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, Thiara Parvinder, Director sold 1,001,633 shares of the company’s stock on Nov 25 ’24. The stock was sold for $2,734,458 at an average price of $2.73. Upon completion of the transaction, the Director now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 11 ’24, Director Thiara Parvinder sold 3,800,000 shares of the business’s stock. A total of $10,260,000 was realized by selling the stock at an average price of $2.70. This leaves the insider owning 1,001,633 shares of the company worth $1.77 million. A total of 27.89% of the company’s stock is owned by insiders.
During the past 12 months, Zura Bio Ltd has had a low of $1.80 and a high of $6.35. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 10.36, and a quick ratio of 10.36. The fifty day moving average price for ZURA is $2.8345 and a two-hundred day moving average price translates $3.708725 for the stock.
The latest earnings results from Zura Bio Ltd (NASDAQ: ZURA) was released for 2024-09-30. The company reported revenue of $19.32 million for the quarter, compared to $10.19 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 89.64 percent.
